More people sent to hospital as mushroom-infused 'microdosing' chocolate faces ongoing FDA probe
How many total hospitalizations have been linked to the consumption of Diamond Shruumz products according to the latest FDA reports?
According to the latest FDA reports, at least 10 people have been hospitalized after consuming Diamond Shruumz products.
What does the term "microdosing" refer to in the context of these chocolate bars, and how is it typically understood in drug use?
The term "microdosing" in the context of these chocolate bars refers to the practice of consuming a small amount of psychedelic substances, such as psilocybin mushrooms, with the aim of enhancing cognitive function, creativity, and mood, without experiencing a full-blown psychedelic trip. Microdosing has gained popularity in recent years as a means to potentially improve mental health and well-being.
In the case of Diamond Shruumz-brand Microdosing Chocolate Bars, the company claims that their products contain a "primo proprietary blend of nootropic and functional mushrooms" without any presence of psilocybin, amanita, or other scheduled drugs. Despite this claim, people who have consumed these chocolate bars have reported severe symptoms, including seizures, central nervous system depression, agitation, abnormal heart rates, and other adverse effects5.
The FDA and CDC are currently investigating the cause of these illnesses and have advised consumers to avoid eating, selling, or serving any flavor of Diamond Shruumz-brand Chocolate Bars, Cones, or Gummies.
What specific symptoms have consumers experienced after consuming Diamond Shruumz-brand Microdosing Chocolate Bars as reported by the FDA?
The FDA has reported that consumers who ate Diamond Shruumz-brand Microdosing Chocolate Bars experienced a variety of severe symptoms. These symptoms include seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, hyper/hypotension, nausea, and vomiting.